Ironwood Pharmaceuticals, Inc. (FRA:I76)

Market Cap	491.03M
Revenue (ttm)	288.92M
Net Income (ttm)	24.33M
Shares Out	n/a
EPS (ttm)	0.15
PE Ratio	20.18
Forward PE	6.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	895
Open	2.840
Previous Close	3.200
Day's Range	2.840 - 2.840
52-Week Range	0.478 - 4.520
Beta	n/a
RSI	72.88
Earnings Date	Feb 13, 2026

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 253
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: I76

Financial Performance

Financial numbers in USD